Australian company Reproductive Health Sciences Limited has just announced that it has entered into an agreement with an Australian IVF provider to give access to the company’s genetic screening technology EmbryoCellect. It is also in discussions with a number of other providers both here and in Indonesia.
This technology is based on work developed at and licensed from the University of Adelaide. ARI also incubated the company in its early stages and faciliated angel and venture capital investment (but ARI no longer holds any equity in the business).
Further information on the technology is available here